Royalty Pharma (NASDAQ: RPRX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Royalty Pharma reported 74 open-market sales of 2,045,840 shares ($92.8m) and 0 open-market purchases, by 5 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 November 2026 | Coyne Terrance P. | EVP & CFO | Conversion | +150,000 | — | 150,000 | Form 4 |
| 6 November 2026 | Coyne Terrance P. | EVP & CFO | Conversion | +100,000 | — | 100,000 | Form 4 |
| 6 November 2026 | Urist Marshall | EVP, Research & Investments | Conversion | +150,000 | — | 150,000 | Form 4 |
| 4 November 2026 | Legorreta Pablo G. | CEO, Chairman of the Board | Grant or award | +42,209 | — | 1,350,029 | Form 4 |
| 4 November 2026 | Hite Christopher | EVP & Chairman, Partnering | Grant or award | +7,122 | — | 277,523 | Form 4 |
| 4 November 2026 | Coyne Terrance P. | EVP & CFO | Grant or award | +7,122 | — | 7,122 | Form 4 |
| 4 November 2026 | Urist Marshall | EVP, Research & Investments | Grant or award | +5,341 | — | 5,341 | Form 4 |
| 5 October 2026 | Urist Marshall | EVP, Research & Investments | Open-market sale, 10b5-1 plan | −4,126 | $57.10 | 0 | Form 4 |
| 30 September 2026 | Bassler Bonnie L | Director | Grant or award | +642 | $58.41 | 79,823 | Form 4 |
| 28 September 2026 | Urist Marshall | EVP, Research & Investments | Open-market sale, 10b5-1 plan | −4,126 | $57.88 | 4,126 | Form 4 |
| 22 September 2026 | Hite Christopher | EVP & Chairman, Partnering | Open-market sale, 10b5-1 plan | −96,073 | $58.51 | 274,328 | Form 4 |
| 22 September 2026 | Hite Christopher | EVP & Chairman, Partnering | Open-market sale, 10b5-1 plan | −3,927 | $58.93 | 270,401 | Form 4 |
| 19 August 2026 | Hite Christopher | EVP & Chairman, Partnering | Gift, 10b5-1 plan | −16,800 | — | 23,200 | Form 4 |
| 18 August 2026 | Hite Christopher | EVP & Chairman, Partnering | Open-market sale, 10b5-1 plan | −100,000 | $59.97 | 370,401 | Form 4 |
| 13 August 2026 | Coyne Terrance P. | EVP & CFO | Open-market sale, 10b5-1 plan | −9,230 | $58.59 | 1,772 | Form 4 |
| 13 August 2026 | Coyne Terrance P. | EVP & CFO | Open-market sale, 10b5-1 plan | −1,772 | $59.14 | 0 | Form 4 |
| 5 August 2026 | Legorreta Pablo G. | CEO, Chairman of the Board | Grant or award | +65,216 | — | 1,307,820 | Form 4 |
| 5 August 2026 | Hite Christopher | EVP & Chairman, Partnering | Grant or award | +11,002 | — | 470,401 | Form 4 |
| 5 August 2026 | Coyne Terrance P. | EVP & CFO | Grant or award | +11,002 | — | 11,002 | Form 4 |
| 5 August 2026 | Urist Marshall | EVP, Research & Investments | Grant or award | +8,252 | — | 8,252 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Royalty Pharma page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.